CDK4 and breast carcinoma: These trials led to the approval of the first-in-class CDK4/6i, palbociclib, followed closely by the approval of two additional CDK4/6 inhibitors, ribociclib and abemaciclib, both in the first-line and second-line settings for ER+ advanced breast cancer [18–20].